

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal649jxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded
NEWS 5 SEP 29 DISSABS now available on STN
NEWS 6 OCT 10 PCTFULL: Two new display fields added
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9 NOV 24 MSDS-CCOHS file reloaded
NEWS 10 DEC 08 CABA reloaded with left truncation
NEWS 11 DEC 08 IMS file names changed
NEWS 12 DEC 09 Experimental property data collected by CAS now available
in REGISTRY
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS 14 DEC 17 DGENE: Two new display fields added
NEWS 15 DEC 18 BIOTECHNO no longer updated
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer
available
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS
databases
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19 DEC 22 ABI-INFORM now available on STN

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:29:06 ON 08 JAN 2004

=> file medline biosis embase caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY SESSION
0.21 0.21

FILE 'MEDLINE' ENTERED AT 12:29:18 ON 08 JAN 2004

FILE 'BIOSIS' ENTERED AT 12:29:18 ON 08 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 12:29:18 ON 08 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:29:18 ON 08 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s slim (s) androgen (s) receptor
L1 0 SLIM (S) ANDROGEN (S) RECEPTOR

=> s slim (p) androgen (p) receptor
L2 0 SLIM (P) ANDROGEN (P) RECEPTOR

=> s slim (p) estrogen (p) receptor
L3 4 SLIM (P) ESTROGEN (P) RECEPTOR

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 1 DUP REM L3 (3 DUPLICATES REMOVED)

=> d l4 ibib

L4 ANSWER 1 OF 1 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 95131407 MEDLINE
DOCUMENT NUMBER: 95131407 PubMed ID: 7830266
TITLE: Rationally designed analogues of tamoxifen with improved
 calmodulin antagonism.
AUTHOR: Hardcastle I R; Rowlands M G; Houghton J; Parr I B; Potter
 G A; Jarman M; Edwards K J; Laughton C A; Trent J O; Neidle
 S
CORPORATE SOURCE: CRC Centre for Cancer Therapeutics, Institute of Cancer
 Research, Sutton, Surrey, U.K.
SOURCE: JOURNAL OF MEDICINAL CHEMISTRY, (1995 Jan 20) 38 (2) 241-8.
 Journal code: 9716531. ISSN: 0022-2623.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199502
ENTRY DATE: Entered STN: 19950307
 Last Updated on STN: 19950307
 Entered Medline: 19950223

=> d l4 total ibib kwic

L4 ANSWER 1 OF 1 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 95131407 MEDLINE
DOCUMENT NUMBER: 95131407 PubMed ID: 7830266
TITLE: Rationally designed analogues of tamoxifen with improved
 calmodulin antagonism.
AUTHOR: Hardcastle I R; Rowlands M G; Houghton J; Parr I B; Potter
 G A; Jarman M; Edwards K J; Laughton C A; Trent J O; Neidle
 S
CORPORATE SOURCE: CRC Centre for Cancer Therapeutics, Institute of Cancer

SOURCE: Research, Sutton, Surrey, U.K.
JOURNAL OF MEDICINAL CHEMISTRY, (1995 Jan 20) 38 (2) 241-8.
Journal code: 9716531. ISSN: 0022-2623.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199502
ENTRY DATE: Entered STN: 19950307
Last Updated on STN: 19950307
Entered Medline: 19950223

AB . . . rational design of more potent antagonists. Compounds with either three or four methylene units in the basic side chain or **slim** lipophilic 4-substituents were expected to be more potent. All compounds were tested for antagonism of the calmodulin-dependent activity of cAMP phosphodiesterase and for binding affinity to the **estrogen receptor** from rat uteri. Some compounds were assayed for cytotoxicity against MCF-7 breast tumor cells in vitro. Introduction of lipophilic 4-substituents. . . butene) by one or two methylene units resulted in modest gains in calmodulin antagonism (10-13). All the compounds assayed retained **estrogen receptor** binding characteristics. The compound possessing the optimal combination of calmodulin antagonism and **estrogen receptor** binding was 12 ((E)-1-[4-[3-(N-pyrrolidino)propoxy]phenyl]-1-(4-iodophenyl)-2-phenyl-1 - butene) (IC50 = 1.1 microM, RBA = 23). Correlation between calmodulin antagonism and cytotoxicity. . .